Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 42
Filtrar
1.
Salud mil ; 42(1): e302, 05/05/2023. ilus, graf, tab
Artigo em Espanhol | LILACS, UY-BNMED, BNUY | ID: biblio-1531521

RESUMO

Introducción: el mieloma múltiple es un trastorno hematológico maligno y el segundo cáncer de la sangre más frecuente. El proceso de la angiogénesis tumoral es fundamental para el crecimiento y metástasis de muchos tipos de tumores, incluido en mieloma múltiple. Se sabe que la sobreexpresión del factor de crecimiento endothelial vascular se encuentra asociado a un mal pronóstico en esta patología, representando un blanco clave para la terapia anti-angiogénica en mieloma múltiple. El anticuerpo monoclonal Bevacizumab es capaz de unirse con gran afinidad al factor de crecimiento endothelial vascular bloqueando su acción. Objetivo: evaluar el Fab(Bevacizumab) marcado con 99mTc o Cy7 como potenciales agentes de imagen moleculares de la expresión de factor de crecimiento endothelial vascular en mieloma múltiple. Material y métodos: la expresión de factor de crecimiento endothelial vascular fue analizada mediante citometría de flujo en la línea celular huaman de mieloma múltiple, la MM1S. Fab(Bevacizumab) fue producido mediante digestión de Bevacizumab con papaína, conjugado a NHS-HYNIC-Tfa y radiomarcado con 99mTc. Se realizaron estudios de biodistribución y de tomografía computarizada por emisión del fotón simple. A su vez, Fab(Bevacizumab) fue marcado con Cy7 para obtener imágenes de fluorescencia in vivo hasta 96 horas. Resultados: el análisis por citometría de flujo en la línea celular MM1S reveló que la expresión de factor de crecimiento endothelial vascular es predominantemente intracelular. Los estudios de biodistribución y SPECT/CT del complejo 99mTc-HYNIC-Fab(Bevacizumab) mostraron una rápida eliminación sanguínea y una significativa captación a nivel renal y tumoral. Las imágenes por fluorescencia empleando Cy7-Fab(Bevacizumab) permitieron la visualización tumoral hasta 96 h p.i. Conclusiones: logramos visualizar la expresión de factor de crecimiento endothelial vascular in vivo en mieloma múltiple mediante el empleo del fragmento Fab del anticuerpo anti-VEGF (Bevacizumab) marcado con 99mTc y Cy7. Estos nuevos agentes de imagen molecular podrían ser empleados potencialmente en el ámbito clínico para la estadificación y el seguimiento de pacientes con mieloma múltiple, mediante la visualización radioactiva in vivo de la expresión de factor de crecimiento endothelial vascular en todo el cuerpo. La imagen óptica de estos trazadores mejoraría el muestreo tumoral y podría guiar la extirpación quirúrgica.


Introduction: Multiple myeloma is a hematologic malignancy and the second most common blood cancer. The process of tumor angiogenesis is central to the growth and metastasis of many types of tumors, including multiple myeloma. Overexpression of vascular endothelial growth factor is known to be associated with poor prognosis in this pathology, representing a key target for anti-angiogenic therapy in multiple myeloma. The monoclonal antibody Bevacizumab is able to bind with high affinity to vascular endothelial growth factor blocking its action. Objective: to evaluate 99mTc- or Cy7-labeled Fab(Bevacizumab) as potential molecular imaging agents of vascular endothelial growth factor expression in multiple myeloma. Methods: Vascular endothelial growth factor expression was analyzed by flow cytometry in the multiple myeloma huaman cell line, MM1S. Fab(Bevacizumab) was produced by digestion of Bevacizumab with papain, conjugated to NHS-HYNIC-Tfa and radiolabeled with 99mTc. Biodistribution and single photon emission computed tomography studies were performed. In turn, Fab(Bevacizumab) was labeled with Cy7 to obtain in vivo fluorescence images up to 96 hours. Results: Flow cytometry analysis in the MM1S cell line revealed that vascular endothelial growth factor expression is predominantly intracellular. Biodistribution and SPECT/CT studies of the 99mTc-HYNIC-Fab(Bevacizumab) complex showed rapid blood clearance and significant renal and tumor uptake. Fluorescence imaging using Cy7-Fab(Bevacizumab) allowed tumor visualization up to 96 h p.i. Conclusions: we were able to visualize vascular endothelial growth factor expression in vivo in multiple myeloma using the Fab fragment of the anti-VEGF antibody (Bevacizumab) labeled with 99mTc and Cy7. These new molecular imaging agents could potentially be employed in the clinical setting for staging and monitoring of patients with multiple myeloma by in vivo radioactive visualization of vascular endothelial growth factor expression throughout the body. Optical imaging of these tracers would improve tumor sampling and could guide surgical excision.


Introdução: O mieloma múltiplo é uma malignidade hematológica e o segundo câncer de sangue mais comum. O processo de angiogênese tumoral é fundamental para o crescimento e a metástase de muitos tipos de tumores, incluindo o mieloma múltiplo. Sabe-se que a superexpressão do fator de crescimento endotelial vascular está associada a um prognóstico ruim no mieloma múltiplo, representando um alvo importante para a terapia antiangiogênica no mieloma múltiplo. O anticorpo monoclonal Bevacizumab é capaz de se ligar com alta afinidade ao fator de crescimento endotelial vascular e bloquear sua ação. Objetivo: avaliar o Fab(Bevacizumab) marcado com 99mTc ou Cy7 como possíveis agentes de imagem molecular da expressão do fator de crescimento endotelial vascular no mieloma múltiplo. Métodos: A expressão do fator de crescimento endotelial vascular foi analisada por citometria de fluxo na linha celular de mieloma múltiplo MM1S. O Fab(Bevacizumab) foi produzido pela digestão do Bevacizumab com papaína, conjugado com NHS-HYNIC-Tfa e radiomarcado com 99mTc. Foram realizados estudos de biodistribuição e tomografia computadorizada por emissão de fóton único. Por sua vez, o Fab(Bevacizumab) foi marcado com Cy7 para geração de imagens de fluorescência in vivo por até 96 horas. Resultados: A análise de citometria de fluxo na linha celular MM1S revelou que a expressão do fator de crescimento endotelial vascular é predominantemente intracelular. Os estudos de biodistribuição e SPECT/CT do complexo 99mTc-HYNIC-Fab(Bevacizumab) mostraram uma rápida depuração sanguínea e uma captação renal e tumoral significativa. A imagem de fluorescência usando Cy7-Fab(Bevacizumab) permitiu a visualização do tumor até 96 horas p.i. Conclusões: Conseguimos visualizar a expressão do fator de crescimento endotelial vascular in vivo no mieloma múltiplo usando o fragmento Fab do anticorpo anti-VEGF (Bevacizumab) marcado com 99mTc e Cy7. Esses novos agentes de imagem molecular poderiam ser usados no cenário clínico para o estadiamento e o monitoramento de pacientes com mieloma múltiplo, visualizando radioativamente a expressão do fator de crescimento endotelial vascular in vivo em todo o corpo. A geração de imagens ópticas desses traçadores melhoraria a amostragem do tumor e poderia orientar a excisão cirúrgica.


Assuntos
Animais , Camundongos , Tecnécio/farmacocinética , Imagem Molecular/métodos , Citometria de Fluxo/métodos , Bevacizumab/farmacocinética , Mieloma Múltiplo/diagnóstico por imagem , Fatores de Crescimento do Endotélio Vascular , Camundongos Endogâmicos BALB C
2.
Int. j. morphol ; 41(2): 333-342, abr. 2023. ilus, tab
Artigo em Inglês | LILACS | ID: biblio-1440309

RESUMO

SUMMARY: Changes in the microcirculation of multiple tissues and organs have been implicated as a possible mechanism in physiological aging. In particular, vascular endothelial growth factor is a secretory protein responsible for regulating angiogenesis via altering endothelial proliferation, survival, migration, extracellular matrix degradation and cell permeability. The aim of the present study was to evaluate the role of vascular endothelial growth factor in the progression of morphological alterations caused by physiological aging in the heart and kidney and to examine its relation to changes in capillary density. We used two age groups of healthy Wistar rats - 6- and 12-month- old. The expression of vascular endothelial growth factor was examined through immunohistochemistry and immunofluorescence and assessed semi-quantitatively. Changes in capillary density were evaluated statistically and correlated with the expression of vascular endothelial growth factor. We reported stronger immunoreactivity for vascular endothelial growth factor in the left compared to the right ventricle and also observed an increase in its expression in both ventricles in older animals. Contrasting results were reported for the renal cortex and medulla. Capillary density decreased statistically in all examined structures as aging progressed. The studied correlations were statistically significant in the two ventricles in 12-month-old animals and in the renal cortex of both age groups. Our results shed light on some changes in the microcirculation that take place as aging advances and likely contribute to impairment in the function of the examined organs.


Los cambios en la microcirculación de múltiples tejidos y órganos se han implicado como un posible mecanismo en el envejecimiento fisiológico. En particular, el factor de crecimiento endotelial vascular es una proteína secretora responsable de regular la angiogénesis mediante la alteración de la proliferación endotelial, la supervivencia, la migración, la degradación de la matriz extracelular y la permeabilidad celular. El objetivo del presente estudio fue evaluar el papel del factor de crecimiento del endotelio vascular en la progresión de las alteraciones morfológicas causadas por el envejecimiento fisiológico en el corazón y riñón y examinar su relación con los cambios en la densidad capilar. Utilizamos dos grupos de ratas Wistar sanas: 6 y 12 meses de edad. La expresión del factor de crecimiento del endotelio vascular se examinó mediante inmunohistoquímica e inmunofluorescencia y se evaluó semicuantitativamente. Los cambios en la densidad capilar se evaluaron estadísticamente y se correlacionaron con la expresión del factor de crecimiento del endotelio vascular. Informamos una inmunorreactividad más fuerte para el factor de crecimiento endotelial vascular en el ventrículo izquierdo en comparación con el derecho y también observamos un aumento en su expresión en ambos ventrículos en animales mayores. Se informaron resultados contrastantes para la corteza renal y la médula. La densidad capilar disminuyó estadísticamente en todas las estructuras examinadas a medida que avanzaba el envejecimiento. Las correlaciones estudiadas fueron estadísticamente significativas en los dos ventrículos en animales de 12 meses y en la corteza renal de ambos grupos de edad. Nuestros resultados arrojan luz sobre algunos cambios en la microcirculación que tienen lugar a medida que avanza el envejecimiento y probablemente contribuyan a un deterioro en la función de los órganos examinados.


Assuntos
Animais , Ratos , Envelhecimento , Vasos Coronários/anatomia & histologia , Coração/anatomia & histologia , Rim/irrigação sanguínea , Capilares/anatomia & histologia , Imuno-Histoquímica , Imunofluorescência , Ratos Wistar , Vasos Coronários/fisiologia , Fatores de Crescimento do Endotélio Vascular/metabolismo , Coração/fisiologia , Rim/anatomia & histologia , Rim/fisiologia , Microcirculação
3.
Rev. méd. Paraná ; 79(1): 106-111, 2021.
Artigo em Português | LILACS | ID: biblio-1282511

RESUMO

- Introdução: As demandas tumorais são supridas pela angiogênese (surgimento de vasos sanguíneos). Em hipóxia, são secretadas moléculas pró-angiogênicas, como o fator de crescimento vascular endotelial (VEGF), ativando vias de progressão, invasão e metástase tumoral; portanto, tais substâncias tornaram-se alvo nas terapias anti-tumorais. Objetivo: Analisar produções científicas sobre câncer e angiogênese, focando em VEGF, seu mecanismo de ação e vias terapêuticas. Método: Revisão integrativa de literatura utilizando base de dados PubMed e Scielo, com os descritores angiogenesis, cancer, VEGF, anti-angiogenic e treatment. Resultados: O VEGF, especialmente VEGF-A, liga-se ao receptor tirosina-quinase VEGFR-2 para induzir a migração de células endoteliais e ativar vias intracelulares, promovendo a liberação de proteases destrutoras da matriz extracelular que permitem o brotamento de vasos sanguíneos. Drogas anti-angiogênicas inibem o mecanismo de VEGF/VEGFR-2. Conclusão: Inibidores de VEGF desaceleram o crescimento neoplásico e melhoram a distribuição sistêmica de fármacos associados, sendo ampla a recomendação da administração conjunta de fármacos anti-angiogênicos e quimioterápicos tradicionais


Introduction: Tumor demands are supplied by angiogenesis (arise of blood vessels). In hypoxia, pro-angiogenic molecules are secreted, as vascular endothelial growth factor (VEGF), which activate pathways of tumor progression, invasion and metastasis. Therefore, such substances have become a target in anti-tumor therapies. Objective: Analyse scientific productions on cancer and angiogenesis, focusing on VEGF, its mechanism and therapeutics pathways. Method: Integrative literature review using the online databases PubMed and Scielo and the terms angiogenesis, cancer, VEGF, anti-angiogenic and treatment. Results: VEGF, especially VEGF-2, binds at VEGFR-2 tyrosine kinase receptor to induce endothelial cells migration and activate intracellular pathways to promote the release of destructive proteases from the extracellular matrix,, which allow blood vessels to sprout. Anti-angiogenic drugs inhibit the mechanism of VEGF/ VEGFR-2. Conclusion: VEGF inhibitors slow neoplastic growth and improve systemic distribution of associated drugs, which are widely recommended in joint administration of traditional anti-angiogenic and chemotherapeutic drugs


Assuntos
Humanos , Fatores de Crescimento do Endotélio Vascular , Neoplasias , Neoplasias/terapia , Inibidores da Angiogênese
4.
Braz. j. med. biol. res ; 54(10): e11028, 2021. tab, graf
Artigo em Inglês | LILACS | ID: biblio-1285653

RESUMO

Engeletin is a natural derivative of Smilax glabra rhizomilax that exhibits anti-inflammatory activity and suppresses lipid peroxidation. In the present study, we sought to elucidate the mechanistic basis for the neuroprotective and pro-angiogenic activity of engeltin in a human umbilical vein endothelial cells (HUVECs) oxygen-glucose deprivation and reoxygenation (OGD/R) model system and a middle cerebral artery occlusion (MCAO) rat model of cerebral ischemia and reperfusion injury. These analyses revealed that engeletin (10, 20, or 40 mg/kg) was able to reduce the infarct volume, increase cerebral blood flow, improve neurological function, and bolster the expression of vascular endothelial growth factor (VEGF), vasohibin-2 (Vash-2), angiopoietin-1 (Ang-1), phosphorylated human angiopoietin receptor tyrosine kinase 2 (p-Tie2), and platelet endothelial cell adhesion molecule-1 (PECAM-1/CD31) in MCAO rats. Similarly, engeletin (100, 200, or 400 nM) markedly enhanced the migration, tube formation, and VEGF expression of HUVECs in an OGD/R model system, while the VEGF receptor (R) inhibitor axitinib reversed the observed changes in HUVEC tube formation activity and Vash-2, VEGF, and CD31 expression. These data suggested that engeletin exhibited significant neuroprotective effects against cerebral ischemia and reperfusion injury in rats, and improved cerebrovascular angiogenesis by modulating the VEGF/vasohibin and Ang-1/Tie-2 pathways.


Assuntos
Animais , Ratos , Traumatismo por Reperfusão/prevenção & controle , Isquemia Encefálica/prevenção & controle , Infarto da Artéria Cerebral Média , Células Endoteliais , Flavonóis , Angiopoietina-1 , Fatores de Crescimento do Endotélio Vascular , Fator A de Crescimento do Endotélio Vascular , Glicosídeos
5.
ABCS health sci ; 45(Supl. 3): e020108, 10 June 2020.
Artigo em Inglês | LILACS | ID: biblio-1252391

RESUMO

Diabetic Macular Edema is a major cause of visual impairment in economically active population, being responsible for a significant impact in quality of life in the affected population, as well as high costs to the health care system. Over decades, some studies have compared treatments using Laser, Anti-VEGF and intravitreous corticosteroids, establishing protocols to reach effectives therapies. Thus, it is essential an entire understanding of available therapies to reach the goal of disease control, in an individual basis and in a collective health care system, as efficient as possible.


Assuntos
Humanos , Edema Macular/terapia , Complicações do Diabetes , Fotocoagulação a Laser , Fatores de Crescimento do Endotélio Vascular , Tomografia de Coerência Óptica , Injeções Intravítreas
6.
Braz. arch. biol. technol ; 63: e20200059, 2020. tab, graf
Artigo em Inglês | LILACS | ID: biblio-1132201

RESUMO

Abstract Hypoxia occurs in the splanchnic region during exercise associated with sympathetic activity. In the elderly, vascular insufficiency and low vascular endothelial growth factor (VEGF) expression are observed. Compared to young people, sympathetic signals of older individuals are blunted and more resistant to splanchnic blood flow alterations during exercise. VEGF induces vasodilation responses and hence may retain blood in the splanchnic vascular bed. We hypothesized that regular mild-intensity exercise triggers weak VEGF expression in the digestive tract of the elderly. The effects of exercise on the levels of VEGF, superoxide dismutase (SOD), glutathione peroxidase (GPx), malondialdehyde (MDA) and total antioxidant capacity (T-AOC) in the stomach, jejunum, ileum and colon tissues were evaluated. With exercise, the VEGF levels in the stomach and colon increased. Although the SOD, GPx, and MDA levels decreased in the stomach, they increased in the colon. T-AOC increased in the stomach and there was no change in the jejunum, ileum and colon. The hypoperfusion during exercise was not equal in all regions of the gastrointestinal tract in the aged subjects. Hypoxia and other exercise-related mechanisms could have led to this VEGF induction. The stomach, jejunum, and ileum might have developed resistance to ischemia. The induction of VEGF may be beneficial in aging-associated impaired gastrointestinal homeostasis and neovascularization.


Assuntos
Animais , Masculino , Ratos , Superóxido Dismutase/sangue , Exercício Físico/fisiologia , Trato Gastrointestinal/metabolismo , Fatores de Crescimento do Endotélio Vascular/metabolismo , Glutationa Peroxidase/sangue , Malondialdeído/sangue , Vasodilatação , Ratos Sprague-Dawley , Teste de Esforço
7.
São Paulo med. j ; 136(6): 543-550, Nov.-Dec. 2018. tab, graf
Artigo em Inglês | LILACS | ID: biblio-991686

RESUMO

ABSTRACT BACKGROUND: Increased angiogenetic activity in inflammatory bowel disease (IBD) has been shown in previous studies. The aim of this study was to evaluate the relationship of serum vascular endothelial growth factor (VEGF) and endostatin levels with clinical features and mucosal expression in patients with ulcerative colitis (UC). DESIGN AND SETTING: Cross-sectional analytical study conducted in a tertiary-level public hospital. METHODS: Serum VEGF and endostatin levels were determined in 82 individuals: 39 with UC, 28 with irritable bowel syndrome (IBS) and 15 healthy controls (HCs), using enzyme-linked immunosorbent assays (ELISA). VEGF and endostatin expressions were studied using immunohistochemistry (IHC). RESULTS: Mean serum VEGF and endostatin levels were significantly higher in patients with UC than in patients with IBS and in HCs (511.9 ± 377.5 pg/ml, 305.0 ± 121.42 pg/ml and 36.1 ± 40.6 pg/ml; P = 0.001 for VEGF; and 155.50 ± 59.8 ng/ml, 116.9 ± 23.8 ng/ml and 102.2 ± 22.4 ng/ml; P < 0.001 for endostatin, respectively). There was a positive correlation between serum VEGF and endostatin levels (r = 0.422; P < 0.01). Mean H-scores for VEGF expression were higher in the active UC group than in the inactive UC and IBS groups, in the stroma, endothelium and epithelium. Mean H-scores for endostatin expression were higher in the active UC group than in the inactive UC and IBS groups, in the stroma and endothelium. There was no endostatin expression in the epithelium. CONCLUSION: Increased endostatin appears to be a defensive reaction to increased VEGF in patients with UC.


Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Colite Ulcerativa/sangue , Síndrome do Intestino Irritável/sangue , Endostatinas/sangue , Fatores de Crescimento do Endotélio Vascular/metabolismo , Mucosa Intestinal/irrigação sanguínea , Ensaio de Imunoadsorção Enzimática , Colite Ulcerativa/patologia , Estudos de Casos e Controles , Estudos Transversais , Síndrome do Intestino Irritável/patologia , Fatores de Crescimento do Endotélio Vascular/sangue , Mucosa Intestinal/metabolismo , Mucosa Intestinal/patologia
8.
Campinas; s.n; 2018. 162 p. ilus, tab.
Tese em Português | LILACS, Inca | ID: biblio-912068

RESUMO

Resumo: Introdução: endometriose é uma doença benigna, capaz de progredir extensamente e gerar clones atípicos. Considerada precursora dos carcinomas de células claras (CCOC) e endometrióide (EOC) de ovário, atualmente chamados carcinomas de ovário associados à endometriose (EAOC). Objetivos: comparar o perfil epidemiológico, a associação com endometriose e a expressão de marcadores imuno-histoquímicos para ARID1A, VEGF, PD-L1 e PARP-1 em mulheres com CCOC e EOC, e sua correlação com a sobrevida livre de progressão (SLP) e sobrevida global (SG). Métodos: estudo de coorte reconstituída, com 50 casos incluídos de CCOC e EOC tratados no CAISM-UNICAMP entre 1995 até 2016, acompanhados até 02/2017. Microarranjos de tecido com amostras de CCOC, EOC e endometriose foram corados com anticorpos monoclonais contra ARID1A, e para os biomarcadores proteicos VEGF, PD-L1, PARP-1 através de imuno-histoquímica. A expressão de ARID1A foi classificada (0 a 100) conforme a porcentagem de células não coradas. A expressão de VEGF, PD-L1 e PARP-1 foi classificada (0 a 300) conforme a multiplicação da porcentagem de células coradas por um fator da intensidade de expressão (ausente=0; fraco=1; moderado=2; forte=3). Idade ao diagnóstico; menopausa; índice de massa corpórea (IMC); CA-125; diagnóstico de endometriose; datas do diagnóstico, da progressão, do óbito e da última consulta foram recuperados dos prontuários. Comparação entre grupos foi realizada através de testes T e de ?2. A SLP (diferença de tempo entre o diagnóstico e a data de progressão) e a SG (diferença de tempo entre o diagnóstico e o óbito ou data da última data de consulta) foi avaliada através de curvas de Kaplan-Meyer e teste de Log-Rank ou regressão de COX. Resultados: 23 mulheres com CCOC (46%), e 27 com EOC (54%) foram incluídas; 80% tinham endometriose associada, 42% eram nulíparas, 42% eram pré-menopausa e CA125 foi elevado em todos estádios (FIGO I-II= média 614.7Ui/mL; FIGO III-IV= media 2361.2Ui/mL). A média de idade ao diagnóstico foi 7 anos menor em mulheres com EOC do que naquelas com CCOC. O CCOC foi mais diagnosticado em estágios iniciais quando associado à endometriose (p=0,03). O prognóstico dos EOC e CCOC em estádios iniciais foi semelhante (p=0,96). Os CCOC não associado à endometriose tiveram menor SG (p=0,04). A expressão de todos os biomarcadores esteve presente nos EAOC e na endometriose. O aumento da expressão de VEGF entre endometriose e câncer foi significativo (p=0,0002). A hiperexpressão de PARP-1 correlacionou-se negativamente com a SLP (p=0,03) e SG (p=0,01) em estádios iniciais. Conclusão: Os CCOC e EOC são comumente diagnosticados em estádios iniciais (FIGO I-II= 68%) e estão frequentemente associados à endometriose (80% dos casos). Quando associados à endometriose, os CCOC foram mais diagnosticados em estádios iniciais e tiveram SG maior. Houve elevada porcentagem de células com ARID1A mutado nos EAOC (>40%). VEGF se expressou mais intensamente nos CCOC e EOC que na endometriose, já a expressão de PD-L1 e de PARP-1 foi similar. Apenas a hiperexpressão de PARP-1 reduziu significativamente a SLP e a SG nos CCOC e EOC nos estádios iniciais(AU)


Abstract: Introduction: Endometriosis is a benign disease, able to progress widely and generate atypical clones. It is a precursor of clear cell ovarian carcinomas (CCOC) and endometrioid ovarian carcinomas (EOCs), now called endometriosis-associated ovarian carcinomas (EAOC). Objectives: To compare the epidemiological profile, association with endometriosis and the expression of immunohistochemical markers for ARID1A, VEGF, PD-L1 and PARP-1 in women with CCOC and EOC, and its correlation with progression-free survival (PFS) and overall survival (OS). Methods: A reconstituted cohort study with 50 cases of CCOC and EOC included. Cases were treated at CAISM-UNICAMP between 1995 and 2016, followed up until 02/2017. Tissue microarrays with CCOC, EOC and endometriosis samples were stained with monoclonal antibodies against ARID1A, and for VEGF, PD-L1, PARP-1 biomarkers by immunohistochemistry. The expression of ARID1A was classified (0 to 100) according to the percentage of unstained cells. The expression of VEGF, PD-L1 and PARP-1 was classified (0 to 300) multiplying the percentage of stained cells by an intensity of expression factor (absent=0, weak=1, moderate=2, strong=3). Age at diagnosis; menopause; BMI (body mass index); CA-125 levels; diagnosis of endometriosis; date of diagnosis, date of progression, date of death and date of last consultation were retrieved from the medical records. Comparison between groups was performed through T and ?2 tests. The PFS (difference in time between diagnosis and progression date) and OS (difference in time between diagnosis and death or the last date of consultation) was assessed using Kaplan-Meyer curves and Log-Rank test or COX multivariate models. Results: twenty-three women with CCOC (46%), and 27 with EOC (54%) were included; 80% had associated endometriosis, 42% were nulliparous, 42% were premenopausal, and CA125 was elevated at all stages (FIGO I-II = mean 614.7Ui / mL; FIGO III-IV = mean 2361.2Ui / mL). The mean age at diagnosis was 7 years lower in women with EOC than in those with CCOC. CCOC when associated with endometriosis were more diagnosed at early stages (p=0.03). The prognosis of EOC and CCOC at early stages was similar (p=0.96). CCOCs not associated with endometriosis had shorter OS (p=0.04). Expression of all biomarkers was present in the EAOC and endometriosis. The increase in VEGF expression between endometriosis and cancer was significant (p=0.0002). The overexpression of PARP-1 correlated negatively with PFS (p=0.03) and OS (p=0.01) at FIGO I-II stages. Conclusion: The diagnosis of women with EOC was made earlier than in those with CCOC. CCOC and EOC are commonly diagnosed in early stages (FIGO I-II - 68%) and were associated with endometriosis (80% of cases). When associated with endometriosis, clear cell carcinomas are more likely diagnosed at early stages, and the association of endometriosis with CCOC improves OS. There was a high percentage of cells with mutated ARID1A gene in EAOC (> 40%). VEGF was expressed more intensely in CCOC and EOC than in endometriosis, whereas expression of PD-L1 and PARP-1 was similar. Only the overexpression of PARP-1 significantly reduced PFS and OS in CCOC and EOC at early stages(AU)


Assuntos
Humanos , Feminino , Prognóstico , Carcinoma Endometrioide , Endometriose , Taxa de Sobrevida , Adenocarcinoma de Células Claras , Fatores de Crescimento do Endotélio Vascular , Endometriose/epidemiologia , Receptor de Morte Celular Programada 1 , Poli(ADP-Ribose) Polimerase-1
9.
J. appl. oral sci ; 26: e20170601, 2018. graf
Artigo em Inglês | LILACS, BBO - Odontologia | ID: biblio-954526

RESUMO

Abstract Despite the successful clinical application of titanium (Ti) as a biomaterial, the exact cellular and molecular mechanisms responsible for Ti osseointegration remains unclear, especially because of the limited methodological tools available in this field. Objective: In this study, we present a microscopic and molecular characterization of an oral implant osseointegration model using C57Bl/6 mice. Material and Methods: Forty-eight male wild-type mice received a Ti implant on the edentulous alveolar crest and the peri-implant sites were evaluated through microscopic (μCT, histological and birefringence) and molecular (RealTimePCRarray) analysis in different points in time after surgery (3, 7, 14 and 21 days). Results: The early stages of osseointegration were marked by an increased expression of growth factors and MSC markers. Subsequently, a provisional granulation tissue was formed, with high expression of VEGFb and earlier osteogenic markers (BMPs, ALP and Runx2). The immune/inflammatory phase was evidenced by an increased density of inflammatory cells, and high expression of cytokines (TNF, IL6, IL1) chemokines (CXCL3, CCL2, CCL5 and CXC3CL1) and chemokine receptors (CCR2 and CCR5). Also, iNOS expression remained low, while ARG1 was upregulated, indicating predominance of a M2-type response. At later points in time, the bone matrix density and volume were increased, in agreement with a high expression of Col1a1 and Col21a2. The remodelling process was marked by peaks of MMPs, RANKL and OPG expression at 14 days, and an increased density of osteoclasts. At 21 days, intimate Ti/bone contact was observed, with expression of final osteoblast differentiation markers (PHEX, SOST), as well as red spectrum collagen fibers. Conclusions: This study demonstrated a unique molecular view of oral osseointegration kinetics in C57Bl/6 mice, evidencing potential elements responsible for orchestrating cell migration, proliferation, ECM deposition and maturation, angiogenesis, bone formation and remodeling at the bone-implant interface in parallel with a novel microscopic analysis.


Assuntos
Animais , Masculino , Implantes Dentários , Osseointegração/fisiologia , Modelos Animais , Implantação Dentária Endóssea/métodos , Interface Osso-Implante/fisiologia , Maxila/cirurgia , Fatores de Tempo , Titânio , Cicatrização , Matriz Óssea/fisiologia , Parafusos Ósseos , Microscopia Eletrônica de Varredura , Biomarcadores/análise , Expressão Gênica , Reprodutibilidade dos Testes , Citocinas/análise , Remodelação Óssea/fisiologia , Fatores de Crescimento do Endotélio Vascular/análise , Microtomografia por Raio-X , Reação em Cadeia da Polimerase em Tempo Real , Interface Osso-Implante/patologia , Maxila/patologia , Camundongos Endogâmicos C57BL
10.
Braz. j. med. biol. res ; 51(2): e6520, 2018. tab, graf
Artigo em Inglês | LILACS | ID: biblio-889032

RESUMO

Multiple growth factors can be administered to mimic the natural process of bone healing in bone tissue engineering. We investigated the effects of sequential release of bone morphogenetic protein-2 (BMP-2) and vascular endothelial growth factor (VEGF) from polylactide-poly (ethylene glycol)-polylactide (PELA) microcapsule-based scaffolds on bone regeneration. To improve the double emulsion/solvent evaporation technique, VEGF was encapsulated in PELA microcapsules, to which BMP-2 was attached. The scaffold (BMP-2/PELA/VEGF) was then fused to these microcapsules using the dichloromethane vapor method. The bioactivity of the released BMP-2 and VEGF was then quantified in rat mesenchymal stem cells (rMSCs). Immunoblotting analysis showed that BMP-2/PELA/VEG promoted the differentiation of rMSCs into osteoblasts via the MAPK and Wnt pathways. Osteoblast differentiation was assessed through alkaline phosphatase expression. When compared with simple BMP-2 plus VEGF group and pure PELA group, osteoblast differentiation in BMP-2/PELA/VEGF group significantly increased. An MTT assay indicated that BMP-2-loaded PELA scaffolds had no adverse effects on cell activity. BMP-2/PELA/VEG promoted the differentiation of rMSCs into osteoblast via the ERK1/2 and Wnt pathways. Our findings indicate that the sequential release of BMP-2 and VEGF from PELA microcapsule-based scaffolds is a promising approach for the treatment of bone defects.


Assuntos
Animais , Coelhos , Ratos , Poliésteres/farmacologia , Polietilenoglicóis/farmacologia , Proteínas Quinases Ativadas por Mitógeno/metabolismo , Fatores de Crescimento do Endotélio Vascular/metabolismo , Alicerces Teciduais , Proteína Morfogenética Óssea 2/metabolismo , Células-Tronco Mesenquimais/citologia , Fatores de Tempo , Regeneração Óssea , Transdução de Sinais/fisiologia , Células Cultivadas , Modelos Animais , Proliferação de Células , beta Catenina/fisiologia , Nanopartículas , Células-Tronco Mesenquimais/efeitos dos fármacos , Células-Tronco Mesenquimais/metabolismo , Via de Sinalização Wnt/fisiologia
11.
Einstein (Säo Paulo) ; 15(4): 403-408, Oct.-Dec. 2017. tab
Artigo em Inglês | LILACS | ID: biblio-891431

RESUMO

ABSTRACT Objective: To evaluate the frequency of polymorphisms in the vascular endothelial growth factor (VEGF) gene, as well as to identify a potential risk haplotype among the polymorphic regions in this gene in patients with disc degeneration and in the Control Group. Methods: This study analyzed a total of 217 individuals distributed into the Disc Degeneration and Control Groups. Peripheral blood was collected from all patients to detect VEGF gene polymorphisms identified by qPCR (rs699947, rs1570360, rs2010963, rs833061 and rs3025039). All patients presenting disc degeneration had the confirmation by nuclear magnetic resonance test and were rated according to disc degeneration level. Results: All polymorphisms were in Hardy- Weinberg equilibrium (p>0.05) in the studied population. The genotypic frequency for Disc Degeneration and Control Group were rs699947 p = 0.475, rs1570360 p = 0.862, rs2010963 p = 0.823, rs833061 p=0.596 and rs3025039 p=0.230. In haplotype analysis, the compositions CAGGC (p=0.094) and CCGGC (p=0.054) stood out. Conclusion: The correlation between VEGF gene polymorphism as a risk predictor for disc degeneration was negative in the studied population. However, the VEGF gene has a large polymorphic region, and it is activated by various catabolic and metabolic factors in the disc degeneration process, which has not been fully elucidated.


RESUMO Objetivo: Avaliar a frequência dos polimorfismos no gene fator de crescimento endotelial vascular (VEGF), bem como identificar potencial haplótipo de risco entre as regiões polimórficas deste gene em pacientes com degeneração discal e em Grupo Controle. Métodos: Este estudo analisou 217 pacientes distribuídos nos Grupos Degeneração Discal e Grupo Controle. Foi coletado sangue periférico de todos os pacientes para a detecção dos polimorfismos do gene VEGF identificados por qPCR (rs699947, rs1570360, rs2010963, rs833061 e rs3025039). Todos os pacientes que apresentaram degeneração discal tiveram a confirmação por meio de ressonância magnética nuclear e avaliação do nível de degeneração do disco. Resultados: Todos os polimorfismos foram encontrados no equilíbrio de Hardy-Weinberg (p>0,05) na população estudada. A frequência genotípica para o Grupo Degeneração de Disco e do Grupo Controle foi rs699947 p=0,475, rs1570360 p=0,862, rs2010963 p=0,823, rs833061 p=0,596 e rs3025039 p=0,230. Para a análise do haplótipo, destacaram-se as composições CAGGC (p=0,094) e CCGGC (p=0,054). Conclusão: A correlação entre os polimorfismos do gene VEGF como preditor de risco para degeneração discal foi negativa na população estudada. No entanto, o VEGF possui grande região polimórfica, ativada por vários fatores catabólicos e metabólicos no processo de degeneração discal, que não está completamente elucidado.


Assuntos
Humanos , Masculino , Feminino , Adulto , Adulto Jovem , Polimorfismo Genético , Haplótipos , Fatores de Crescimento do Endotélio Vascular/genética , Degeneração do Disco Intervertebral/genética , Variação Genética , Imageamento por Ressonância Magnética , Estudos de Casos e Controles , Medição de Risco , Fatores de Crescimento do Endotélio Vascular/fisiologia , Alelos , Reação em Cadeia da Polimerase em Tempo Real/métodos , Frequência do Gene , Genótipo , Pessoa de Meia-Idade
12.
Acta cir. bras ; 32(12): 1045-1055, Dec. 2017. graf
Artigo em Inglês | LILACS | ID: biblio-886197

RESUMO

Abstract Purpose: To evaluate the effect of transforming growth factor β1 (TGF-β1) on tendon-to-bone reconstruction of rotator cuff tears. Methods: Seventy-two rat supraspinatus tendons were transected and reconstructed in situ. At 8 and 16 weeks, specimens of three groups; that is control, L-dose (low dose), and H-dose (high dose) were harvested and underwent a biomechanical test to evaluate the maximum load and stiffness values. Histology sections of the tendon-to-bone interface were identified by hematoxylin-eosin or Masson trichrome stain. Collagen type III was observed by picric acid sirius red staining under polarized light. The level of insulin-like growth factor 1 (IGF-1) and vascular endothelial growth factor (VEGF) was measured by the enzyme-linked immunosorbent assay (ELISA) method. Results: Collagen type III of the H-dose group had a significant difference in histology structure compared with the L-dose group (P<0.05). The maximum load and stiffness decreased significantly in the control group compared with the values of the L-dose and H-dose groups. The stiffness among the three groups differed significantly at the same postoperative time (P<0.05). Interestingly, progressive reestablishment of collagen type III affected tendon-to-bone healing significantly in the later stages. Conclusion: The H-dose was associated with an increased collagen type III morphology stimulated by TGF-β1.


Assuntos
Animais , Masculino , Ratos , Traumatismos dos Tendões/tratamento farmacológico , Cicatrização/fisiologia , Manguito Rotador/cirurgia , Fatores de Crescimento do Endotélio Vascular/metabolismo , Fator de Crescimento Transformador beta1/metabolismo , Lesões do Manguito Rotador/cirurgia , Traumatismos dos Tendões/metabolismo , Resistência à Tração/fisiologia , Cicatrização/efeitos dos fármacos , Fenômenos Biomecânicos , Ensaio de Imunoadsorção Enzimática , Manguito Rotador/metabolismo , Ratos Sprague-Dawley , Colágeno Tipo III/metabolismo , Modelos Animais de Doenças , Elasticidade/fisiologia , Fator de Crescimento Transformador beta1/farmacologia , Força Muscular/fisiologia , Fibroblastos/efeitos dos fármacos , Fibroblastos/fisiologia , Lesões do Manguito Rotador/metabolismo
13.
Arq. bras. oftalmol ; 80(4): 252-256, July-Aug. 2017. tab, graf
Artigo em Inglês | LILACS | ID: biblio-888121

RESUMO

ABSTRACT Purpose: To evaluate and compare the effects of topical application and subconjunctival injection of bevacizumab on corneal neovascularization (CNV) in rabbits' eyes after chemical burning of the cornea. Methods: The animals were randomly distributed into four groups of five animals. In one group, the drug was instilled, while in another, it was administered by subconjunctival injection. The two procedures using bevacizumab were compared with instillation and subconjunctival injection of saline solution (S). Neovascularization was evaluated according to the size of the invasion area of new blood vessels and through computerized analysis of this area. The data were analyzed using the Kruskal-Wallis test followed by Dunn's test for two-by-two comparison of the groups, to assess the external examination of CNV. Analysis of variance was used to assess the area of CNV. P<0.05 was considered statistically significant. Results: Assessing both the external examination and the invasion area of neovessels on the 5th and 10th days, there was a clear difference between the groups. The group to which saline solution had been applied showed higher scores for CNV, as well as increases in the invasion area of neovessels. Two-by-two comparison of groups revealed no significant differences. However, an analysis of the factors involved (injection vs. instillation and bevacizumab vs. saline solution) showed that injection did not differ from instillation, but that bevacizumab differed from saline solution. Conclusion: Bevacizumab showed an inhibitory effect on CNV in rabbits' eyes after chemical burning of the cornea. There was no difference between the topical or subconjunctival administration of bevacizumab in the inhibition of CNV.


RESUMO Objetivos: Avaliar e comparar o efeito do uso tópico e da injeção subconjuntival do bevacizumabe na neovascularização corneana de olhos de coelhos após queimadura química. Métodos: Os animais foram distribuídos de forma aleatória em quatro grupos de cinco animais. Em um grupo de coelhos a droga foi instilada, enquanto em outro foi aplicada injeção subconjuntival, sendo os dois procedimentos comparados com a instilação e injeção subconjuntival de soro fisiológico 0,9% (SF) e entre si. A neovascularização foi avaliada conforme o tamanho da área de invasão dos neovasos e com análise computadorizada da mesma. Na análise de dados aplicou-se o teste de Kruskal-Wallis seguido do teste de Dunn com p<0,05 para comparação dos grupos dois a dois na análise do exame externo da neovascularização corneana. Na análise da área de neovascularização corneana, aplicou-se o teste F de análise de variância. A significância estatística foi definida como valor de p<0.05. Resultados: A avaliação do exame externo e da área de invasão de neovasos, no 5º e 10º dia, mostrou nítida diferença entre os grupos. Com o uso de soro fisiológico houve maior graduação na escala de neovascularização corneana e também na área de invasão dos nevasos, o que demonstrou o efeito inibitório do bevacizumabe. Nas comparações dos grupos dois a dois não foram detectadas diferenças significativas, porém, ao analisar os fatores envolvidos (procedimentos: injeção ou instilação, e as drogas: bevacizumabe ou soro fisiológico), verificou-se que a injeção não diferiu da instilação, mas o bevacizumabe diferiu do soro fisiológico. Conclusão: O bevacizumabe apresentou efeito inibitório na neovascularização corneana de olhos de coelhos após queimadura química, tanto por via tópica como por via subconjuntival e não houve diferença entre a via tópica e a via subconjuntival de administração do bevacizumabe na inibição da neovascularização corneana.


Assuntos
Animais , Masculino , Ratos , Neovascularização da Córnea/tratamento farmacológico , Córnea/efeitos dos fármacos , Inibidores da Angiogênese/administração & dosagem , Bevacizumab/administração & dosagem , Soluções Oftálmicas , Queimaduras Químicas , Distribuição Aleatória , Queimaduras Oculares , Administração Tópica , Neovascularização da Córnea/patologia , Córnea/inervação , Fatores de Crescimento do Endotélio Vascular/antagonistas & inibidores , Modelos Animais de Doenças , Injeções Intraoculares , Lesões da Córnea/induzido quimicamente
14.
Clinics ; 71(11): 639-643, Nov. 2016. tab, graf
Artigo em Inglês | LILACS | ID: biblio-828547

RESUMO

OBJECTIVE To investigate immunohistochemical markers of angiogenesis and their association with pathological prognostic features in hepatocellular carcinoma and cirrhotic liver. METHODS Vascular endothelial growth factor, CD105, and cyclooxygenase-2 were immunohistochemically detected in 52 hepatocellular carcinoma tissue samples and 48 cirrhotic liver tissue samples. Semiquantitative measurements of vascular endothelial growth factor and cyclooxygenase-2 were evaluated considering the degree and intensity of immunostaining based on a 7-point final scoring scale. CD105 microvascular density (MVD-CD105) was measured using automated analysis. Morphological aspects evaluated in the hepatocellular carcinoma samples included size (≤2 and >2 cm), differentiation grade, and microvascular invasion. RESULTS The mean vascular endothelial growth factor immunoreactivity score was slightly higher in the hepatocellular carcinoma samples (4.83±1.35) than the cirrhotic liver (4.38±1.28) samples. There was a significant and direct correlation between these mean scores (rs=0.645, p=0.0001). Cyclooxygenase-2 was expressed in all the cirrhotic liver samples but was only found in 78% of the hepatocellular carcinoma samples. The mean cyclooxygenase-2 score was higher in the cirrhotic liver samples (4.85±1.38) than the hepatocellular carcinoma samples (2.58±1.68), but there was no correlation between the scores (rs=0.177, p=0.23). The mean CD105 percentage in the hepatocellular carcinoma samples (11.2%) was lower than that in the cirrhotic samples (16.9%). There was an inverse relationship in MVD-CD105 expression between the hepatocellular carcinoma and cirrhotic samples (rs=-0.78, p=0.67). There were no significant associations between vascular endothelial growth factor expression and morphological characteristics. Cyclooxygenase-2 and CD105 were associated with hepatocellular carcinoma differentiation grade (p=0.003 and p=0.05, respectively). CONCLUSION Vascular endothelial growth factor, cyclooxygenase-2, and MVD-CD105 were highly expressed in cirrhotic liver compared to hepatocellular carcinoma and might be involved in liver carcinogenesis. Additionally, cyclooxygenase-2 and CD105 might be involved in hepatocellular carcinoma differentiation grade.


Assuntos
Humanos , Masculino , Feminino , Adolescente , Adulto , Pessoa de Meia-Idade , Idoso , Adulto Jovem , Carcinoma Hepatocelular/patologia , Ciclo-Oxigenase 2/metabolismo , Endoglina/metabolismo , Cirrose Hepática/metabolismo , Neoplasias Hepáticas/patologia , Fatores de Crescimento do Endotélio Vascular/metabolismo , Biomarcadores Tumorais/metabolismo , Carcinoma Hepatocelular/irrigação sanguínea , Carcinoma Hepatocelular/metabolismo , Endotélio Vascular/metabolismo , Imuno-Histoquímica , Neoplasias Hepáticas/irrigação sanguínea , Neoplasias Hepáticas/metabolismo , Gradação de Tumores , Estatísticas não Paramétricas
15.
Acta cir. bras ; 31(8): 513-519, Aug. 2016. tab, graf
Artigo em Inglês | LILACS | ID: lil-792411

RESUMO

ABSTRACT PURPOSE: To investigate the effects of pharmacological delay with insulin-like growth factor-1 (IGF-1) on skin flap survival. METHODS: Thirty Sprague-Dawley rats were submitted to dorsal skin flap (3x9 cm). Seven days before the surgery, the animals were subdivided into three groups of 10 rats. In group 1 (controls), no injection was done. Seven days before the elevation, saline had been injected to the marked skin flap area in group 2 (sham group), and group 3 (experimental group) underwent a pharmacological delay with subcutaneous IGF-1 injections. On the seventh postoperative day, flap area was analyzed for survival. Tissue samples were obtained for histological and biochemical evaluations. RESULTS: Survival rates were 43.55 ± 16%, 21.40 ± 8%, and 43.12 ± 14% in groups 1, 2, and 3, respectively. Differences between group 2 and other groups were statistically significant. No significant difference was detected between all three groups for tissue or plasma vascular endothelial growth factor (VEGF) levels. There was no significant histological difference between groups. CONCLUSION: Although a single injection of insulin-like growth factor-1 (IGF-1) did not significantly increase flap survival, its wound healing features are still encouraging and further meticulously planned studies, especially with repeated applications or controlled-release methods, and combinations with binding protein are required.


Assuntos
Animais , Ratos , Retalhos Cirúrgicos/fisiologia , Cicatrização/efeitos dos fármacos , Fator de Crescimento Insulin-Like I/farmacologia , Sobrevivência de Enxerto/efeitos dos fármacos , Anti-Inflamatórios/farmacologia , Retalhos Cirúrgicos/irrigação sanguínea , Fator de Crescimento Insulin-Like I/administração & dosagem , Ratos Sprague-Dawley , Fatores de Crescimento do Endotélio Vascular/sangue , Injeções Subcutâneas , Anti-Inflamatórios/administração & dosagem
16.
Natal; s.n; fev. 2016. 136 p. tab, ilus.
Tese em Português | LILACS, BBO - Odontologia | ID: lil-790526

RESUMO

As neoplasias de glândulas salivares exibem uma grande diversidade morfológica e comportamentos biológicos variados o que suscita o interesse na pesquisa destas lesões. A disseminação das células tumorais é um passo inicial para a progressão de neoplasias malignas e, dentro deste contexto, os vasos linfáticos neoformados são considerados essenciais para que ocorra essa disseminação. O papel do VEGF (fator de crescimento endotelial vascular) na formação dos vasos é fato conhecido mas, pouco se sabe a respeito de sua participação em tumores de glândula salivar. Desta forma, o objetivo deste estudo foi avaliar a expressão do VEGF-C e VEGF-D, a densidade linfática tumoral (D2-40) e a proliferação endotelial linfática (dupla marcação D2-40/Ki-67) em uma série de neoplasias de glândulas salivares. A amostra foi composta por 20 adenomas pleomórficos, 20 carcinomas adenóides císticos, 20 carcinomas mucoepidermóides e 10 casos de tecido glandular salivar com características de normalidade para efeito comparativo. Todos os casos estudados exibiram expressão positiva para VEGF-C em região peritumoral e intratumoral, não sendo encontrada diferenças de imunoexpressão entre os grupos. No entanto, o grupo dos carcinomas adenóides císticos demonstrou diferença significativa da imunoexpressão do VEGF-C segundo o padrão cribriforme e sólido (p = 0,004). A maioria dos casos constantes do presente estudo, apresentou fraca marcação para VEGF-D em região peritumoral e intratumoral...


Salivary gland neoplasms exhibit a great morphological diversity and varied biological behavior which raises the interest in the study of these lesions. The spread of tumor cells is an early step in the progression of malignancies and the neoformed lymphatic vessels are considered essential in tumor dissemination. Vascular endotelial growth fator (VEGF) is a family of proteins involved in angiogenesis e lymphangiogenesis. However, in salivar tumors we have limited information on the expression. The aim of this study was to assess the expression of VEGF-C and VEGF-D, lymphatic vessel density (single-staining D2-40) and lymphatic endothelial proliferation (double labeling D2-40/Ki-67) in a series of salivary glands neoplasms. We selected 20 cases of pleomorphic adenoma, 20 of mucoepidermoide carcinoma, 20 of adenoid cystic carcinoma and 10 tissue sample of normal salivary gland. All cases studied showed positive expression of VEGF-C in intratumoral and peritumoral region, no differences in immunoreactivity was found between the groups. However, the group of adenoid cystic carcinoma showed a significant difference in immunoreactivity of VEGF-C by the cribriform and solid pattern (p = 0.004). Most of the cases included in this study showed weak immunoreactivity for VEGF-D in intratumoral and peritumoral region. In the assessment of lymphatic endotelial density peritumoral, intratumoral and total, the groups showed an increasing gradient, with lower values for the group of pleomorphic adenomas followed by mucoepidermoid carcinoma and adenoid cystic carcinoma. Lymphatic endothelial cell density was higher in malignant than benign tumors. No correlation was observed between the immunoreactivity of VEGF-C and VEGF-D in relation to tumor lymphatic density and lymphatic endothelial proliferation.


Assuntos
Adenoma Pleomorfo/patologia , Carcinoma Mucoepidermoide/patologia , Glândulas Salivares/patologia , Linfangiogênese , Fator de Crescimento do Endotélio Vascular Derivado de Glândula Endócrina , Fatores de Crescimento do Endotélio Vascular , Carcinoma Adenoide Cístico/patologia , Imuno-Histoquímica , Estatísticas não Paramétricas
17.
Oncol. clín ; 21(2): 47-50, 2016. ilus, tab
Artigo em Espanhol | LILACS | ID: biblio-882187

RESUMO

Los eventos tromboembólicos cerebrales están asociados con secuelas permanentes y con deterioro de la calidad de vida. Sangrados, trastornos venosos y arteriales han sido descriptos con el uso de agentes antiangiogénicos. Presentamos un caso con sarcoma mixoide que desarrolló un accidente cerebrovascular isquémico mientras estaba siendo tratado con sorafenib. Repasamos también las drogas usadas en oncología que podrían estar asociadas con eventos tromboembólicos arteriales o venosos. Los médicos tratantes deberían monitorear a los pacientes que reciben agentes antiangiogénicos en relación a síntomas neurológicos y, en ausencia de otras etiologías, la pronta suspensión de la droga debería ser considerada (AU)


The cerebral thromboembolic events are linked with permanent sequelae and deterioration in quality of life. Bleeding, venous and arterial thromboembolic events have been described with antiangiogenics agents. We report a case with myxoid sarcoma that developed a cerebrovascular accident while on sorafenib treatment. We also reviewed drugs used in oncology that could be associated with arterial and venous thromboembolic events. Physicians should monitor patients receiving antiangiogenics agents for neurologic symptoms and in the absences of other etiology, prompt discontinuation of these drugs should be considered (AU)


Assuntos
Humanos , Masculino , Idoso , Inibidores da Angiogênese/uso terapêutico , Transtornos Cerebrovasculares , Ataque Isquêmico Transitório/etiologia , Inibidores da Angiogênese/efeitos adversos , Acidente Vascular Cerebral , Fatores de Crescimento do Endotélio Vascular
18.
Rev. Soc. Colomb. Oftalmol ; 48(1): 68-82, 2015.
Artigo em Espanhol | LILACS, COLNAL | ID: biblio-948865

RESUMO

Objetivos: Presentar una revisión de los nuevos y posibles objetivos de tratamiento farmacológicos para la degeneración macular relacionada a la edad neovascul r y el estado de los fármacos en estudios clínicos. Diseño del estudio: Revisión de tema. Métodos: Se realizó una búsqueda de la literatura electrónica disponible en EMBASE, PUBMED y Google Scholar acerca del tema, y se complementa con la información encontrada en www.clinicaltrials.gov y la plataforma de registros internacionales de ensayos clínicos de la O.M.S. Se procedió a sistematizar la información y se presenta en forma estructurada. Conclusiones: Las nuevas opciones terapéuticas para la degeneración macular relacionada la edad neovascular proporcionan múltiples objetivos farmacológicos, los cuales se alcanzan realizando modificaciones a moléculas ya elaboradas o con nuevos fármacos los cuales pueden actuar tanto como terapia adjunta a los actuales medicamentos antiangiogénicos (anti VEGF) mejorando su eficacia o con nuevas opciones sustitutivas. Meritorio destacar la vía de la tirosina-quinasa, la cual había sido abordada con los existentes anti VEGF, ahora se presentan nuevas opciones terapéuticas que actúan corriente abajo. Diversos fármacos se encuentran en estudios de efi cacia parcial, merecen especial mención Fovista® y conbercept de los cuales ya se encuentran en desarrollo estudios fase III.


Objectives: To present a review of new and potential targets for pharmacological treatment for neovascular age-related macular degeneration and the state of drugs in development of clinical studies. Study design: Literature review. Methods: A search of electronic literature available in EMBASE, PubMed and Google Scholar on the subject is made and compliments the information found on www.clinicaltrials. gov and platform of international clinical trials registers of the W.H.O. Conclusions: N ew therapeutic options for neovascular age-related macular degeneration provide multiple targets, which are achieved by performing modifi cations to a molecule already developed or new drugs which can act both as an adjunct to current anti VEGF improving efficiency or new alternative options. Meritorious note the tyrosine kinase way, on which previously it has acted with existing anti VEGF, now presents new therapeutic options that act downstream. Several drugs are in partial effi cacy studies, deserve special mention Fovista and conbercept of which already studies are in development phase III.


Assuntos
Degeneração Macular/tratamento farmacológico , Fatores de Crescimento do Endotélio Vascular , Degeneração Macular/diagnóstico
19.
An. bras. dermatol ; 89(6): 891-897, Nov-Dec/2014. tab, graf
Artigo em Inglês | LILACS | ID: lil-727638

RESUMO

BACKGROUND: Angiogenesis is an early stage of psoriatic lesion development, but less is known about lymphagiogenesis and its role in the development of psoriasis. OBJECTIVE: To examine the expression of specific lymphatic markers and lymphatic growth factors in untreated psoriatic skin, in the unaffected skin of patients and skin of healthy volunteers, as well as their alteration after treatment with an anti-TNF agent. METHODS: Immunohistochemistry for the lymphatic markers D2-40 and LYVE-1, in addition to the VEGF-C and VEGF-D growth factors, was performed in the skin biopsies of psoriatic lesions and adjacent non-psoriatic skin of 19 patients before and after treatment with etanercept, as well as in the skin biopsies of 10 healthy volunteers. RESULTS: The expressions of D2-40, VEGF-C and VEGF-D on lymphatic vessels underwent statistically significant increases in untreated psoriatic skin compared with non-lesional skin, in contrast to LYVE-1, which did not involve significant increase in expression in psoriatic skin. VEGF-C expression on lymphatic vessels diminished after treatment with etanercept. Moreover VEGF-C and VEGF-D staining on fibroblasts presented with higher expression in lesional skin than in non-lesional adjacent skin. CONCLUSION: Remodeling of lymphatic vessels possibly occurs during psoriatic lesion development, parallel to blood vessel formation. The exact role of this alteration is not yet clear and more studies are necessary to confirm these results. .


Assuntos
Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Anticorpos Monoclonais Murinos/análise , Vasos Linfáticos/patologia , Psoríase/tratamento farmacológico , Fatores de Necrose Tumoral/antagonistas & inibidores , Fatores de Crescimento do Endotélio Vascular/análise , Proteínas de Transporte Vesicular/análise , Anticorpos Monoclonais Murinos/efeitos dos fármacos , Biópsia , Biomarcadores/análise , Imuno-Histoquímica , Imunoglobulina G/uso terapêutico , Fatores Imunológicos/uso terapêutico , Linfangiogênese/efeitos dos fármacos , Vasos Linfáticos/efeitos dos fármacos , Psoríase/metabolismo , Psoríase/patologia , Valores de Referência , Receptores do Fator de Necrose Tumoral/uso terapêutico , Estatísticas não Paramétricas , Pele/efeitos dos fármacos , Pele/patologia , Fatores de Crescimento do Endotélio Vascular/efeitos dos fármacos , Proteínas de Transporte Vesicular/efeitos dos fármacos
20.
Acta ortop. bras ; 22(5): 250-255, Sep-Oct/2014. tab, graf
Artigo em Inglês, Português | LILACS | ID: lil-783283

RESUMO

Apresentar uma série de 50 casos consecutivos de pacientescom osteossarcoma de extremidade não metastático, e tentarcorrelacionar a expressão da proteína VEGF na biópsia com o prognóstico– sobrevida global, sobrevida livre da doença e recorrêncialocal. Métodos: Cinquenta casos de osteossarcoma de extremidadenão metastático tratados entre 1986 e 2006 no Instituto de Ortopediae Traumatologia da Universidade de São Paulo São Paulo, Brasil,foram avaliados quanto à expressão de VEGF. Havia 19 pacientesfemininos e 31 masculinos. A média de idade foi 16 anos (intervalo,5-28 anos) e o seguimento médio foi de 60,6 meses (intervalo, 25-167 meses). As variáveis estudadas foram idade, gênero, localizaçãoanatômica, tipo de cirurgia, margens cirúrgicas, tamanho do tumor,necrose pós-quimioterapia, recorrência local, metástases pulmonarese morte. Resultados: Trinta e seis pacientes mostraram expressãode VEGF igual ou menor a 30% das células (baixo), e os 14 restantesmostraram expressão de VEGF acima de 30% (alto). Entre os 36pacientes com baixa expressão, nove desenvolveram metástasespulmonares e quatro morreram (11,1%). Entre os 14 pacientes comalta expressão de VEGF, seis desenvolveram metástases pulmonarese três morreram (21,4%). Conclusão: Não houve correlaçãosignificativa entre a expressão de VEGF com nenhuma das variáveisestudadas. Nível de Evidência IV, Estudo Terapêutico...


To present a series of 50 consecutive patients withnon-metastatic extremity osteosarcoma, and attempt to correlateexpression of the VEGF protein in biopsy tissue to their prognosisregarding overall survival, disease-free survival and local recurrence.Methods: Fifty cases of non-metastatic osteosarcoma ofthe extremities treated between 1986 and 2006 at Instituto deOrtopedia e Traumatologia da Universidade de São Paulo, SãoPaulo, Brasil, were evaluated regarding expression of the VEGFprotein. There were 19 females and 31 males. The mean age was16 years old (range 5-28 years old) and the mean follow-up was60.6 months (range 25-167 months). The variables studied wereage, gender, anatomic location, type of surgery, surgical margins,tumor size, post chemotherapy necrosis, local recurrence, pulmonarymetastasis and death. Results: Thirty-six patients showedVEGF expression on 30% or less cells (low), and the remaining14 cases had VEGF expression above 30% (high). Among the 36patients with low VEGF expression, nine developed pulmonarymetastasis and four died (11.1%). Among the 14 patients withhigh VEGF expression, six developed pulmonary metastasis andthree died (21.4%). Conclusion: There was no statistically significantcorrelation between the expression of VEGF and any of thevariables studied. Level of Evidence IV, Therapeutic Study...


Assuntos
Humanos , Masculino , Feminino , Criança , Adolescente , Adulto , Análise de Sobrevida , Fatores de Crescimento do Endotélio Vascular , Neovascularização Patológica , Osteossarcoma , Prognóstico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA